Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Espié

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 3, 2007
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjectsMaria Laura Sargentini-Maier, Pascal Espié, Alain Coquette, et al.
Drug Metabolism Reviews|July 16, 2009
Physiologically based pharmacokinetics (PBPK)Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 25, 2019
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibodyPascal Espié, YanLing He, Phillip Koo, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 3, 2007
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjectsMaria Laura Sargentini-Maier, Pascal Espié, Alain Coquette, et al.
Drug Metabolism Reviews|July 16, 2009
Physiologically based pharmacokinetics (PBPK)Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 25, 2019
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibodyPascal Espié, YanLing He, Phillip Koo, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|November 21, 2023
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized studyBaltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, et al.
The Lancet. Rheumatology|January 24, 2024
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyBenjamin A Fisher, Antonia Szanto, Wan-Fai Ng, et al.
Pageof 1